Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anamorelin in NSCLC-Cachexia (ROMANA 1)
NCT01387269Phase 3Completed
- Start
- Jul 2011
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in cancer cachexia comparing Anamorelin 100 mg with Placebo (2 arms). Primary endpoints: Change in Lean Body Mass at 12 weeks and Change in Handgrip Strength at 12 weeks. Started Jul 2011; status: completed.
02
Drugs
anamorelin
03
Conditions
cancer cachexia
Beyond the preview
Go deeper on NCT01387269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01387269.